• Asia Pacific focused Biosimilars event in Singapore
  •  Latest Biosimilar Case Studies
  •   Country focused updates

IBC Asia conferences
IBC Asia conferences

According to report published by GrandViewResearch.com has announced the addition of Biosimilars Market revenue is expected to reach USD 41.7 billion by 2024, global biosimilars market is anticipated to witness a marked growth during the period of 2016 to 2024.

Asia Pacific exhibits a large scale demand for biosimilars due to the growing prevalence of chronic diseases in these regions. Collaboration with local players is proven as the key opportunity for biosimilars in developing economies. IBC’s 2nd Annual Biosimilars APAC Summit discusses the market readiness and future uptake of biosimilars development of regulatory frameworks, best practice commercialisation strategies, and advancement of processes with focus on drug substance.

2016 Key Themes

  • Commercialisation & Investment Schemes of Biosimilars
  • Biosimilars vs. Biobetters
  • Biosimilarity Extrapolation & Interchangeability
  • Advances in Biosimilar Production & Technologies
  • Scale Up of Biosimilars
  • Upstream & Downstream Process Development & Characterisation

View all agenda »

Featured Industry Speakers

Paul Song
Vice President and Head of Cell Engineering Team
Samsung Bioepis, South Korea

Edward Madden
Head of Legal (Global), Biosimilars
Biogen, Switzerland
Srinivasan Raman
Vice President & Head of Malaysia Operations
Biocon Sdn Bhd, Malaysia

Daniel Furtner
Senior Medical Manager, Therapeutic Area Lead Rheumatology & Biotherapeutics Japan-Asia-Pacific, Global Medical Affairs, AbbVie, Singapore

Ikhsan Rambia
Regulatory Affairs Manager, Business Development Team,
Sanbe Farma, Indonesia

View all speakers »

Produced byExhibitors  


Past Media Partners